- £218.75bn
- £236.77bn
- $54.07bn
- 78
- 14
- 98
- 73
REG - AstraZeneca PLC - US FDA accepts regulatory submission for Lynparza
AnnouncementREG - AstraZeneca PLC - Farxiga significantly reduced hospitalisation for
AnnouncementREG - AstraZeneca PLC - AZN: Year-to-Date and Q3 2018 Results
AnnouncementREG - AstraZeneca PLC - Divestment of rights to Covis Pharma
AnnouncementREG - AstraZeneca PLC - Total Voting Rights
AnnouncementREG - AstraZeneca PLC - Additional financial information-Grünenthal deal
AnnouncementREG - AstraZeneca PLC - Grünenthal Agreement for rights to Nexium, Vimovo
AnnouncementREG - AstraZeneca PLC - AstraZeneca Extends Innate Pharma Collaboration
AnnouncementREG - AstraZeneca PLC - Lynparza shows 70% reduction in PFS ovarian cancer
AnnouncementREG - AstraZeneca PLC - CHMP positive opinion Bevespi Aerosphere
AnnouncementREG - AstraZeneca PLC - FDA Orphan Drug for Lynparza in pancreatic cancer
AnnouncementREG - AstraZeneca PLC - Total Voting Rights
AnnouncementREG - AstraZeneca PLC - Atacand Agreement with Cheplapharm Completed
AnnouncementREG - AstraZeneca PLC - Previous Announcement Regarding Appointment Of NED
AnnouncementREG - AstraZeneca PLC - Overall survival data for Imfinzi: Stage III NSCLC
AnnouncementREG - AstraZeneca PLC - EMA approves AZ's Imfinzi for Stage III NSCLC
AnnouncementREG - AstraZeneca PLC - Farxiga gets positive result in DECLARE-TIMI 58
AnnouncementREG - AstraZeneca PLC - FDA approves AZ's Lumoxiti in hairy cell leukaemia
AnnouncementREG - AstraZeneca PLC - Tezepelumab FDA Breakthrough Therapy Designation
Announcement